TOPLINE: A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates effectiveness against infections and associated hospitalizations in veterans aged 60 years or older during the 2023-2024 respiratory illness season. This protection extends across age groups and immunocompromised individuals. METHODOLOGY: Researchers conducted a target trial emulation study to evaluate the real-world effectiveness of …
Leave a Comment Leave a Comment
